Scroll to learn more
Plain language summaries are the outcome of the clinical trial journey for a participant
We work with our industry peers to enhance how companies may share clinical trial information with our participants, consistent with applicable laws and regulations
As part of our patient focused drug development approach here at AbbVie, we provide results summaries about completed trials in an easy and understandable manner while upholding our commitments to trade associations principles and the European Union (EU) Clinical Trials Regulation requirements.
A summary of clinical trial results for laypersons, referred to as a lay summary of results or plain language summary (PLS), is a brief description of the clinical trial results in everyday language that is understandable to people who do not have a medical or scientific background.
Sharing plain language summaries of completed clinical trials with study participants can give them valuable insights into the clinical trial journey and illustrate the valuable role they have provided. AbbVie has been disclosing PLS since 2019.
View Available Plain Language Summaries
Scientific results summaries are shared to supplement publicly accessible information.
Our scientific result summaries share the results of our clinical trials and the evidence used to approve a new medicine or indication
Scientific result summaries are available for all AbbVie sponsored trials that were conducted in patients, regardless of the phase of the trial or the age of the study participants. These summaries are redacted to respect patient privacy, third party agreements and protect company confidential information.
For interventional trials that completed since May 2004, we post scientific result summaries within 12 months of the regulatory approval or for trials with approved products and indications within 12 months from the date that the last patient in the trial had their last study visit.
For observational studies that completed since October 2012, we post scientific result summaries within 12 months from the date that the last patient in the trial had their last study visit.